Phase I, single and multi-dose, placebo controlled, randomized, dose-escalation study to evaluate the safety, tolerability and PK [pharmacokinetic] profile of MP-376 [levofloxacin] using the PARI eFlow nebulizer for 14 days to CF [cystic fibrosis] patients
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Levofloxacin (Primary)
- Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Adverse reactions
- Sponsors Horizon Pharma; Mpex Pharmaceuticals
- 23 Oct 2008 Results have been reported in an Mpex Pharmaceuticals media release.
- 23 Oct 2008 Results will be presented at the North American Cystic Fibrosis Conference according to an Mpex Pharmaceuticals media release.
- 23 Apr 2008 Status changed from recruiting to completed, reported by ClinicalTrials.gov.